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Babies born preterm are at an increased risk of dying in the first weeks of life, and those who
survive have a higher rate of cerebral palsy (CP) compared with babies born at term. The
aim of this individual participant data (IPD) meta-analysis (MA) was to assess the effects of
antenatal magnesium sulphate, compared with no magnesium treatment, given to women
at risk of preterm birth on important maternal and fetal outcomes, including survival free of
CP, and whether effects differed by participant or treatment characteristics such as the rea-
son the woman was at risk of preterm birth, why treatment was given, the gestational age at
which magnesium sulphate treatment was received, or the dose and timing of the adminis-
tration of magnesium sulphate.
Methods and findings
Trials in which women considered at risk of preterm birth (<37 weeks’ gestation) were rando-
mised to magnesium sulphate or control treatment and where neurologic outcomes for the
baby were reported were eligible for inclusion. The primary outcomes were infant death or
CP and severe maternal outcome potentially related to treatment. Studies were identified
based on the Cochrane Pregnancy and Childbirth search strategy using the terms [antenatal
or prenatal] and [magnesium] and [preterm or premature or neuroprotection or ’cerebral
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palsy’]. The date of the last search was 28 February 2017. IPD were sought from investiga-
tors with eligible trials. Risk of bias was assessed using criteria from the Cochrane Collabo-
ration. For each prespecified outcome, IPD were analysed using a 1-stage approach. All 5
trials identified were included, with 5,493 women and 6,131 babies. Overall, there was no
clear effect of magnesium sulphate treatment compared with no treatment on the primary
infant composite outcome of death or CP (relative risk [RR] 0.94, 95% confidence interval
(CI) 0.85 to 1.05, 6,131 babies, 5 trials, p = 0.07 for heterogeneity of treatment effect across
trials). In the prespecified sensitivity analysis restricted to data from the 4 trials in which the
intent of treatment was fetal neuroprotection, there was a significant reduction in the risk of
death or CP with magnesium sulphate treatment compared with no treatment (RR 0.86,
95% CI 0.75 to 0.99, 4,448 babies, 4 trials), with no significant heterogeneity (p = 0.28). The
number needed to treat (NNT) to benefit was 41 women/babies to prevent 1 baby from
either dying or having CP. For the primary outcome of severe maternal outcome potentially
related to magnesium sulphate treatment, no events were recorded from the 2 trials provid-
ing data. When the individual components of the composite infant outcome were assessed,
no effect was seen for death overall (RR 1.03, 95% CI 0.91 to 1.17, 6,131 babies, 5 trials) or
in the analysis of death using only data from trials with the intent of fetal neuroprotection (RR
0.95, 95% CI 0.80 to 1.13, 4,448 babies, 4 trials). For cerebral palsy in survivors, magne-
sium sulphate treatment had a strong protective effect in both the overall analysis (RR 0.68,
95% CI 0.54 to 0.87, 4,601 babies, 5 trials, NNT to benefit 46) and the neuroprotective intent
analysis (RR 0.68, 95% CI 0.53 to 0.87, 3,988 babies, 4 trials, NNT to benefit 42). No statisti-
cally significant differences were seen for any of the other secondary outcomes. The treat-
ment effect varied little by the reason the woman was at risk of preterm birth, the gestational
age at which magnesium sulphate treatment was given, the total dose received, or whether
maintenance therapy was used. A limitation of the study was that not all trials could provide
the data required for the planned analyses so that combined with low event rates for some
important clinical events, the power to find a difference was limited.
Conclusions
Antenatal magnesium sulphate given prior to preterm birth for fetal neuroprotection prevents
CP and reduces the combined risk of fetal/infant death or CP. Benefit is seen regardless of
the reason for preterm birth, with similar effects across a range of preterm gestational ages
and different treatment regimens. Widespread adoption worldwide of this relatively inexpen-
sive, easy-to-administer treatment would lead to important global health benefits for infants
born preterm.
Author summary
Why was the study done?
• Effective therapies that can reduce the risk of neurological impairments and disabilities
from preterm birth are needed.
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• Antenatal magnesium sulphate given to women at imminent risk of preterm birth
reduces the risk of cerebral palsy in their babies in aggregate data meta-analysis.
• The aims of the AMICABLE (Antenatal magnesium sulphate individual participant
data international collaboration: Assessing the benefits for babies using the best level of
evidence) individual participant data meta-analysis (IPD-MA) were to assess the effect
of antenatal magnesium sulphate when given to women at risk of preterm birth on
important clinical outcomes and whether treatment effects varied depending on partici-
pant and treatment factors.
What did the researchers do and find?
• Five randomised trials with 5,493 women and 6,131 babies were identified as including
women at risk of preterm birth who were allocated magnesium sulphate or control
treatment and in which neurologic outcomes for the baby were reported and included.
• Antenatal magnesium sulphate given to women at imminent risk of preterm birth for
fetal neuroprotection prevents cerebral palsy and reduces the combined risk of fetal/
infant death or cerebral palsy.
• Benefit was seen regardless of the reason for preterm birth, across a range of preterm
gestational ages, and with minimal variation in outcomes related to time prior to birth
or dosage given.
What do these findings mean?
• Antenatal magnesium sulphate for fetal neuroprotection can be recommended to be
given close to planned or expected preterm birth using the smallest effective dose of 4 g
with or without a 1 g/hour maintenance dose.
• Antenatal magnesium sulphate is an inexpensive, effective treatment that can reduce the
burden of death and cerebral palsy in babies born very preterm.
• Widespread adoption of recommendations to use antenatal magnesium sulphate prior
to preterm birth could lead to significant global health benefits.
Introduction
Worldwide, each year, almost 15 million babies are born preterm (before 37 completed weeks
of gestation)—11% of all births [1]. Babies born preterm are at greater risk of dying in early life
compared with those born at term [2,3]. Preterm babies who survive have a higher risk for
neurologic impairments, such as cerebral palsy, blindness, deafness, or cognitive dysfunction,
and, as a result, are at greater risk of substantial disability [4]. The earlier the gestation at birth
is, the greater these risks become. Global estimates suggest that up to 8% of preterm babies
have neurological impairments, of which 5% are mild and 3% moderate or severe [5]. Cerebral
palsy and cognitive dysfunction, either intellectual impairment or developmental delay, are the
most frequent cause of neurological impairment. With the rate of preterm birth increasing in
many countries, more babies are at risk of dying and, among those who survive, of having an
adverse neurological outcome, making the global burden substantial [6]. Effective therapies
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that can reduce the risk of neurological impairments and disabilities for preterm survivors are
urgently needed.
The linkage of antenatal magnesium sulphate to a reduction in cerebral palsy arose from
seminal observational studies in the mid-1990s [7,8]. Several randomised trials followed, the
latest reported in 2008 [9,10,11,12,13]. When the Cochrane review assessing the use of magne-
sium sulphate for women at risk of preterm birth for neuroprotection of the fetus was updated
in 2009 [14], for the first time, a clinically important reduction in the risk of cerebral palsy was
identified using aggregate data meta-analysis methods. There was a relative risk reduction of
nearly a third in cerebral palsy (32%) in children born to women allocated magnesium sulphate
prior to preterm birth compared with controls. Although the absolute risk reduction of 1.7%
for cerebral palsy was small, it represented a huge advance in minimising a burden of illness
that has so far proved very resistant to intervention. The exact mechanism by which magne-
sium exerts a neuroprotective effect is unclear. Magnesium sulphate can block cerebral gluta-
mate receptors, and this may prevent posthypoxic brain injury in the perinatal period [14].
The Cochrane review was unable to provide some details needed by guideline developers,
policy makers, clinicians, and pregnant women—notably, whether antenatal magnesium sul-
phate treatment is more effective in some women by reason of their risk of preterm birth, what
the gestational age range is for maximal benefit, what dose and timing prior to birth is best,
and whether maintenance treatment or retreatment is necessary [15,16]. The AMICABLE
(Antenatal magnesium sulphate individual participant data international collaboration:
Assessing the benefits for babies using the best level of evidence) Group was formed to under-
take a meta-analysis of the individual participant data of the eligible trials. The advantages of
individual participant data meta-analysis (IPD-MA) for exploring interactions between treat-
ment and participant-level characteristics and enabling examination of differential treatment
effects between subgroups are well described [17,18,19]. The objectives of the AMICABLE
IPD-MA were to assess, using IPD methods and meta-analyses, the effects of administration of
antenatal magnesium sulphate given to women at risk of preterm birth on important clinical
outcomes.
Methods
The Children, Youth and Women’s Health Service Research Ethics Committee, South Austra-
lia, Australia, approved the study (REC2315/10/13). The included trials had received country-
specific ethical review, with individual participants providing written, informed consent. The
IPD meta-analysis followed the published protocol (S2 Text) [20], and the results are reported
using the Preferred Reporting Items for Systematic Review and Meta-analyses of Individual
Participant Data (PRISMA-IPD Statement) checklist (S1 Text) [21].
Specific objectives
The specific objectives of the AMICABLE IPD-MA were to assess whether the treatment
effects of antenatal magnesium sulphate given to women at risk of preterm birth differ depend-
ing on the following important prespecified participant and treatment characteristics [20]:
• the reason the woman was considered to be at risk of preterm birth (such as preterm labour,
hypertensive disease of pregnancy, antepartum haemorrhage, or presence of ruptured
membranes);
• the primary reason antenatal magnesium sulphate treatment was given (such as neuropro-
tection of the fetus, pre-eclampsia, or tocolysis);
• the number of babies in utero (singleton or multiple);
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• the gestational age at which antenatal magnesium sulphate treatment was given;
• the time prior to birth when antenatal magnesium sulphate treatment was given;
• the type, mode of administration, and dosage of antenatal magnesium sulphate planned and
given;
• whether maintenance treatment with antenatal magnesium sulphate was planned and used;
and
• whether repeat antenatal magnesium sulphate treatment was planned and used.
Eligibility criteria
Trials in which women considered at raised risk of preterm birth (less than 37 weeks’ gesta-
tion) were randomised to either magnesium sulphate or no treatment were considered eligible.
Trials were included if the primary aim of the study was to prevent neurologic abnormalities
in the unborn baby or if the primary aim was otherwise but early childhood neurological out-
comes were reported for the infants. Quasirandom study designs were not eligible.
Identifying studies: Information sources and search strategy
The search strategy developed by the Cochrane Pregnancy and Childbirth Group [22] was
used. This identified trials from monthly searches of the Cochrane Central Register of Con-
trolled Trials (CENTRAL); weekly searches of MEDLINE; monthly searches of CINAHL
(EBSCO); hand-searches of 30 journals and the proceedings of major conferences; and weekly
current awareness alerts for a further 44 journals, plus monthly BioMed Central email alerts.
Searches used the terms [antenatal or prenatal] and [magnesium] and [preterm or prema-
ture or neuroprotection or ’cerebral palsy’]. The date of the last search was 28 February 2017.
In addition, the World Health Organisation (WHO)/CTRP portal was accessed to identify any
recently completed or ongoing trials. The date of the last search was 3 May 2017. There was no
language restriction on the searches. Trialists within the AMICABLE Group were asked if they
knew of any unpublished or other trials.
Study selection processes
Eligibility for inclusion of the identified trials was assessed independently by 2 unblinded
members of the AMICABLE Project Team (PFM and TKB). Any differences in opinion
regarding eligibility were resolved by discussion. For the MAGPIE Trial [12], the primary aim
of the study was neuroprotection of the mother with pre-eclampsia rather than neuroprotec-
tion of the fetus. Childhood neurological outcomes were available from centres selected for
longer-term follow-up. Data were included from participants in the longer-term follow-up
who were preterm at trial entry (<37 weeks’ gestation).
Data collection processes and data items
The chair of the AMICABLE Project Team contacted the investigators of all eligible studies to
invite them to join the AMICABLE Trialist Group and to include IPD from their trial in the
meta-analysis.
Prespecified and clearly defined variables (both for participant-level and trial-level factors
as well as for outcomes) were identified and confirmed by the AMICABLE Trialist Group.
Investigators were asked whether these variables had been collected or could be derived for
their study. A coding system was developed from these variables.
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Deidentified data were collected on all women randomised. These included baseline data
for descriptive purposes and analyses (reason at raised risk of preterm birth, gestational age at
trial entry, plurality of the pregnancy, and expected date of birth) and details of the interven-
tion planned and given (the date of randomisation, the allocated intervention, the type and
dose of magnesium sulphate given, the mode of administration, whether a maintenance dose
was given, and whether retreatment was given and its amount), together with the maternal
and infant outcomes to allow the planned analyses.
The individual trial data were recoded as required and stored in a custom-designed secure
database only accessible by authorised personnel from the AMICABLE Data Management
Group. Trialists from the individual trials were asked to verify their own coded data prior to
the analyses.
Data were checked with respect to range, internal consistency, missing or extreme values,
errors, and consistency with the published reports. Trial details such as randomisation
methods and intervention details were cross-checked against trial protocols, clinical record
forms, and published reports. The AMICABLE biostatistician, project, and data managers
liaised closely with the investigators from the individual trials to clarify any inconsistencies
and missing data. Each trial was analysed individually, and the final IPD dataset generated
for each trial was sent to the appropriate trial investigator for verification before synthesis-
ing into the full AMICABLE dataset. Data items collected are published elsewhere (S3 Text)
[20].
IPD integrity
Risk of bias assessment in individual studies. Using the Cochrane Collaboration risk of
bias tool [23], the risk of bias for each study was assessed independently by 2 members of the
AMICABLE Project Team (PFM and TKB), with differences resolved by discussion. Each
study was judged to have a high, low, or unclear risk of bias for random sequence generation
(checking for possible selection bias), allocation concealment (checking for possible selection
bias), blinding of participants and personnel (checking for possible performance bias), blind-
ing of outcome assessment (checking for possible detection bias), incomplete outcome data
(checking for possible attrition bias due to the amount, nature, and handling of incomplete
outcome data), selective reporting (checking for reporting bias), and other bias (checking for
bias due to problems not already covered). The magnitude and direction of the bias and
whether it was considered likely to affect the findings were assessed. Additional information
was sought from the trialists if any aspect was unclear.
Specification of outcomes and effect measures. The 2 primary prespecified outcomes
were a composite of death (defined as any fetal death after randomisation or death of a live-
born infant before follow-up) or cerebral palsy for the infant (as defined by the trialists and cat-
egorised as mild, moderate, or severe) and, for the mother, any severe maternal outcome
potentially related to treatment (defined as death, respiratory arrest, or cardiac arrest). Second-
ary outcomes were prespecified in the protocol (S4 Text) [20].
Synthesis methods
A detailed statistical analysis plan was prepared by the AMICABLE Data Management Group
and agreed upon by the AMICABLE Trialist Group prior to the data analyses. All analyses
were based on the checked and updated IPD from all trials. All randomised participants with
outcome data available were included in the analyses, which were performed on an intention-
to-treat basis, according to the treatment allocation at randomisation. No changes were made
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to the prespecified analysis plan. Further description of the statistical methods is included in
the protocol [20].
For each of the outcomes, a 1-stage approach to analysis was taken so that the IPD from all
eligible trials were included in a single model. Fitting a single model for each outcome variable
enabled the variation across trials to be accounted for within the model. A treatment-by-trial
interaction term was tested to assess heterogeneity of treatment effect across trials. If there was
excessive statistical heterogeneity in the treatment effect across trials (i.e., the trial-by-treat-
ment interaction term was significant), then the rationale for combining trials was questioned
and the source of heterogeneity explored.
Binary outcomes were analysed using log-binomial regression models, and the results are
presented as relative risk RR) with 95% confidence intervals (CIs) and associated 2-sided p-val-
ues. Continuous outcomes were analysed using linear regression models, and the results are
presented as differences in means with 95% CIs and 2-sided p-values. Correlations between
outcomes due to multiple births were taken into account using generalised estimating equa-
tions (GEEs), when appropriate.
Any differences in treatment effect between prespecified subgroups were assessed by testing
a treatment by subgroup interaction term within the model. If data were missing for an out-
come, those participants were removed from the analysis for that outcome. Reasons for miss-
ingness were explored, when possible. For each outcome, if there were unbalanced or large
amounts of missing endpoint data for at least 1 trial, then sensitivity analyses were undertaken
to assess the impact of removing such trials from the analysis.
Categorical outcomes were analysed using proportional odds models. Analyses of raw
growth measurements (head circumference, weight, and length) were adjusted for age cor-
rected for prematurity and sex, and analyses of WHO calculated z-scores of growth measure-
ments were unadjusted for age and sex.
Missing data were accounted for in the following 2 ways. The main method for accounting
for missing data for binary outcomes was to assume that participants with no data for that out-
come did not have the outcome. This is referred to as the ‘Impute “No”‘ method.
Secondly, for the primary outcome (death or CP) missing CP values at follow-up were
imputed using multiple imputations (MIs). One hundred MI datasets were imputed using the
Stata version 11.2 ‘ice’ (MI using chained equations) function. Counts and percentages within
each treatment group for MI analyses represent average percentages in the imputed datasets.
Trial-specific estimates and standard errors for imputed analyses are from MI GEE models
adjusting for correlation between multiple births. Overall relative risk estimates for meta-anal-
yses containing results from the MI models were calculated using a 2-stage aggregate meta-
analysis approach with inverse variance weighting.
The following sensitivity analyses were conducted:
1. exclusion of trials that were not for the purpose of neuroprotection of the fetus
2. exclusion of trials with high rates of participant exclusions, where losses were considered to
have the potential to affect the results.
Results
Study characteristics
Seven randomised trials were identified through database searching [9,10,11,12,13,24,25], 2 of
which were ongoing randomised trials [24,25]. Five randomised controlled trials were identi-
fied from the search, and each contributed data for the IPD meta-analyses (Fig 1)
[9,10,11,12,13]. Details of the studies are described in Table 1.
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Fig 1. Preferred Reporting Items for Systematic Review and Meta-analyses of Individual Participant Data
(PRISMA-IPD) flow diagram. Abbreviations: CP, cerebral palsy.
https://doi.org/10.1371/journal.pmed.1002398.g001
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IPD integrity
Overall, the risk of bias was low in the included studies, with some variation between trials
(Table 2).
Risk of bias across studies
There was a generally low risk of bias across the studies, except for 3 of the 5 studies in which
the risk of bias associated with attrition was rated as unclear.
Primary outcomes
A. Death or cerebral palsy. There was no statistically significant effect of antenatal treat-
ment with magnesium sulphate on the composite outcome death or cerebral palsy in infants in
the combined analyses (Table 3).
In the prespecified sensitivity analysis of the 4 trials with fetal neuroprotective intent, there
was a statistically significant reduction in the risk of death or cerebral palsy (Table 4) with no
Table 1. Included studies and their characteristics.
Trial Name Participants included in IPD Interventions Outcomes
ACTOMgSO4
[9]
1,062 women (1,255 fetuses) at <30
weeks’ gestation likely to give birth within
24 hours.
Active treatment: 4 g magnesium sulphate
intravenously over 20 minutes and then 1 g/
hour until birth or for 24 hours, whichever
came first. Placebo group: equal volume of
0.9% saline.
Primary outcomes: total paediatric mortality
(stillbirths, deaths up to 2 years of age,
cerebral palsy, and combined outcome of
death or cerebral palsy). Maternal
outcomes: adverse cardiovascular and
respiratory effects of infusion.
PREMAG [10] 564 women (691 fetuses) in labour at <33
weeks’ gestation.
Active treatment: 4 g magnesium sulphate
over 30 minutes. Placebo group: equal
volumes of 0.9% saline.
Primary outcomes: infant death or white
matter injury on cranial ultrasound.
Secondary outcomes included follow-up of
children at 2 years of age.
MAGNET [11] 149 women (166 fetuses) in preterm labour
at 25–33 weeks’ gestation, with or without
premature rupture of the membranes.
‘Tandem’ randomisation: (1) Eligible for
aggressive tocolysis (cervix 4 cm dilation).
Magnesium sulphate tocolysis: 4 g bolus and
then 2–3 g/hour maintenance (n = 46). ‘Other’
tocolysis (n = 46). (2) Not eligible for tocolysis
(cervix > 4 cm dilatation). Neuroprotective
magnesium sulphate: 4 g bolus alone
(n = 29). Saline control (n = 28).
Fetal and later mortality, IVH, cerebral palsy,
and death or cerebral palsy at 18 months of
age.
MAGPIE [12] 1,544 women (1,575 fetuses); a subset of
women in the Magpie Trial who were <37
weeks’ gestation with severe pre-
eclampsia and randomised prior to birth in
centres included in long-term follow-up.
Active treatment: 4 g magnesium sulphate
intravenously over 10–15 minutes, followed
by either 1 g/hour intravenously for 24 hours
or by 5 g every 4 hours intramuscularly for 24
hours. Placebo: equal volumes of 0.9%
saline.
Primary outcomes: eclampsia and death of
the baby before hospital discharge.
Secondary endpoints included long-term
outcomes for the children. Data for
paediatric mortality and cerebral palsy were
provided at 18 months of age.
BEAM [13] 2,241 women (2,444 fetuses) at 24 to <32
weeks’ gestation, at high risk of
spontaneous birth due to ruptured
membranes at 22–31 weeks’ GA, or
advanced preterm labour with dilatation
4–8 cm and intact membranes. Individuals
were also included if an indicated preterm
birth was anticipated within 24 hours.
Active treatment: 6 g magnesium sulphate
intravenously over 20–30 minutes, followed
by maintenance infusion of 2 g/hour. If
delivery had not occurred after 12 hours and
was no longer considered imminent, the
infusion was discontinued and resumed when
delivery threatened. Placebo group received
an ‘identical-appearing placebo’.
Primary outcomes: composite of (1) stillbirth
or infant death by 1 year of age or (2)
moderate or severe cerebral palsy at or
beyond 2 years of age (corrected).
Abbreviations: ACTOMgSO4, Australasian Collaborative Trial of Magnesium Sulphate; BEAM, Beneficial Effects of Antenatal Magnesium Sulfate; GA,
gestational age; IPD, individual participant data; IVH, intraventricular haemorrhage; MAGNET, Magnesium and Neurologic Endpoints Trial; MAGPIE,
MAGnesium sulphate for Prevention of Eclampsia; PREMAG, PREterm brain protection by MAGnesium sulphate
https://doi.org/10.1371/journal.pmed.1002398.t001
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significant heterogeneity (p = 0.28). The number needed to treat (NNT) to benefit was 41
women/babies to prevent 1 baby from either dying or having cerebral palsy (CP).
B. Severe adverse maternal events related to treatment. There were no events for the
primary outcome of severe adverse maternal events related to treatment (including death or
respiratory or cardiac arrest) and, accordingly, no events for maternal death or for severe
maternal adverse events reported separately (total of 1,635 women: [9,10]).
C. Paediatric mortality. For the primary paediatric outcome of mortality, the overall
mortality rates were 14.3% for babies exposed to magnesium sulphate and 13.6% for those
exposed to the control treatment, not a statistically significant effect (Table 5).
D. Cerebral palsy. There was a strong protective effect of magnesium sulphate on the rate
of CP, both for all studies (NNT to benefit 46 babies) (Table 6) and for the analysis limited to
the fetal neuroprotective studies only (NNT to benefit 42 babies) (Table 7).
Overall, there were significant reductions in the rates of both moderate and severe CP com-
bined (event rates 2.12% MgSO4, 3.36% controls; RR 0.63, 95% CI 0.44 to 0.90) and severe CP
Table 2. Risk of bias within studies.
Trial Randomisation1 Concealment2 Blinding3 Attrition4 Reporting5
ACTOMgSO4 [9] low low low low low
PREMAG [10] low low low unclear low
MAGNET [11] unclear unclear unclear unclear unclear
MAGPIE [12] low low low unclear low
BEAM [13] low low low low low
Abbreviations: ACTOMgSO4, Australasian Collaborative Trial of Magnesium Sulphate; BEAM, Beneficial Effects of Antenatal Magnesium Sulfate;








Table 3. Death or cerebral palsy* (all trials).
Trial MgSO4 Control Relative risk 95% confidence interval
ACTOMgSO4 [9] 123/629 (19.6%) 150/626 (24.0%) 0.83 0.67–1.04
PREMAG [10] 56/353 (15.9%) 68/338 (20.1%) 0.76 0.54–1.07
MAGNET [11] 13/86 (15.1%) 4/80 (5.0%) 2.80 0.94–8.34
MAGPIE [12] 202/790 (25.6%) 182/ 785 (23.2%) 1.07 0.90–1.28
BEAM [13] 148/1,188 (12.5%) 173/1,256 (13.8%) 0.91 0.85–1.05
Overall† 542/3,046 (17.8%) 577/3,085 (18.7%) 0.94 0.85–1.05
Abbreviations: ACTOMgSO4, Australasian Collaborative Trial of Magnesium Sulphate; BEAM, Beneficial Effects of Antenatal Magnesium Sulfate;
MAGNET, Magnesium and Neurologic Endpoints Trial; MAGPIE, MAGnesium sulphate for Prevention of Eclampsia; PREMAG, PREterm brain protection
by MAGnesium.
*Available data (participants were included if either death or cerebral palsy [CP] outcome known).
†p-value for heterogeneity = 0.07 (the heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and
trial in a generalising estimating equation [GEE] model).
https://doi.org/10.1371/journal.pmed.1002398.t003
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Table 4. Death or cerebral palsy (sensitivity analysis: trials with a primary intent of fetal neuroprotection)*.
Trial MgSO4 Control Relative risk 95% confidence interval
ACTOMgSO4 [9] 123/629 (19.6%) 150/626 (24.0%) 0.83 0.67–1.04
PREMAG [10] 56/353 (15.9%) 68/338 (20.1%) 0.76 0.54–1.07
MAGNET [11] 5/28 (17.9%) 1/30 (3.3%) 5.36 0.66–43.20
BEAM [13] 148/1,188 (12.5%) 173/1,256 (13.8%) 0.91 0.74–1.12
Overall 332/2,198 (15.1%) 392/2,550 (17.4%) 0.86 0.75–0.99
Abbreviations: ACTOMgSO4, Australasian Collaborative Trial of Magnesium Sulphate; BEAM, Beneficial Effects of Antenatal Magnesium Sulfate;
MAGNET, Magnesium and Neurologic Endpoints Trial; MgSO4, magnesium sulphate; PREMAG, PREterm brain protection by MAGnesium sulphate.
*Available data (participants were included if either death or cerebral palsy [CP] outcome known).
https://doi.org/10.1371/journal.pmed.1002398.t004
Table 5. Paediatric death (fetal, neonatal, or later death) at any time* (all trials).
Trial MgSO4 Control Relative risk 95% confidence interval
ACTOMgSO4 [9] 87/629 (13.8%) 108/626 (17.3%) 0.81 0.62–1.07
PREMAG [10] 34/353 (9.6%) 38/338 (11.2%) 0.83 0.52–1.32
MAGNET [11] 10/86 (11.6%) 1/80 (1.3%) 8.11 1.05–62.69
MAGPIE [12] 200/790 (25.3%) 177/785 (22.5%) 1.09 0.91–1.30
BEAM‡ [13] 105/1,188 (8.8%) 97/1,256 (7.7%) 1.15 0.88–1.51
Overall† 436/3,046 (14.3%) 421/3,085 (13.6%) 1.03 0.91–1.17
Abbreviations: ACTOMgSO4, Australasian Collaborative Trial of Magnesium Sulphate; BEAM, Beneficial Effects of Antenatal Magnesium Sulfate;
MAGNET, Magnesium and Neurologic Endpoints Trial; MAGPIE, MAGnesium sulphate for Prevention of Eclampsia; MgSO4, magnesium sulphate;
PREMAG, PREterm brain protection by MAGnesium sulphate.
*Available data.
‡The BEAM trial only recorded deaths in the first 12 months of life
†p-value for heterogeneity = 0.07 (the heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and
trial in a generalising estimating equation [GEE] model).
https://doi.org/10.1371/journal.pmed.1002398.t005
Table 6. Cerebral palsy (as defined by trialists)* (all trials).
Trial MgSO4 Control Relative risk 95% confidence interval
ACTOMgSO4 [9] 36/533 (6.8%) 42/513 (8.2%) 0.83 0.54–1.28
PREMAG [10] 22/313 (7.0%) 30/293 (10.2%) 0.68 0.40–1.17
MAGNET [11] 3/60 (5.0%) 3/62 (4.8%) 1.03 0.22–4.94
MAGPIE [12] 2/236 (0.8%) 5/255 (2.0%) 0.43 0.08–2.21
BEAM [13] 43/1,133 (3.8%) 77/1,203 (6.4%) 0.59 0.41–0.86
Overall† 106/2,275 (4.7%) 157/2,326 (6.7%) 0.68 0.54–0.87
Abbreviations: ACTOMgSO4, Australasian Collaborative Trial of Magnesium Sulphate; BEAM, Beneficial Effects of Antenatal Magnesium Sulfate;
MAGNET, Magnesium and Neurologic Endpoints Trial; MAGPIE, MAGnesium sulphate for Prevention of Eclampsia MgSO4, magnesium sulphate;
PREMAG, PREterm brain protection by MAGnesium sulphate.
*Available data (participants were included if the cerebral palsy [CP] outcome was known).
†p-value for heterogeneity = 0.74 (the heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and
trial in a generalising estimating equation [GEE] model).
https://doi.org/10.1371/journal.pmed.1002398.t006
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alone (event rates 0.81% MgSO4, 1.50% controls; RR 0.54, 95% CI 0.30 to 0.94), with no signifi-
cant heterogeneity among trials for either outcome.
Maternal secondary outcomes
Of the maternal secondary outcomes, the only statistically significant effect was an increase in
adverse events leading to stopping treatment in the magnesium sulphate group (Table 8).
There were no clear differences in infectious morbidity (19.1% magnesium sulphate versus
18.8% control), mode of birth by caesarean (48% versus 46.3%), or postpartum haemorrhage
(28.1% versus 28.1%).
Neonatal secondary outcomes
No statistically significant differences or any significant heterogeneity were seen in any of the
analyses for the other neonatal morbidity dichotomous outcomes reported or defined by the
trialists, including Apgar score at 5 minutes < 7, active resuscitation at birth, use of ongoing
respiratory support after birth, any intraventricular haemorrhage (IVH), severe IVH (grade 3
Table 7. Cerebral palsy (sensitivity analysis: trials with a primary intent of fetal neuroprotection)*.
Trial MgSO4 Control Relative risk 95% confidence interval
ACTOMgSO4 [9] 36/533 (6.8%) 42/513 (8.2%) 0.83 0.54–1.28
PREMAG [10] 22/313 (7.0%) 30/293 (10.2%) 0.68 0.40–1.17
MAGNET [11]‡ 3/23 (13.0%) 0/23 (0%) – –
BEAM [13] 43/1,133 (3.8%) 77/1,203 (6.4%) 0.59 0.41–0.86
Overall† 101/1,979 (5.1%) 149/2,009 (7.4%) 0.68 0.53–0.87
Abbreviations: ACTOMgSO4, Australasian Collaborative Trial of Magnesium Sulphate; BEAM, Beneficial Effects of Antenatal Magnesium Sulfate;
MAGNET, Magnesium and Neurologic Endpoints Trial; MgSO4, magnesium sulphate; PREMAG, PREterm brain protection by MAGnesium sulphate. The
denominators exclude the deaths of infants/children.
*Available data (participants were included if the cerebral palsy [CP] outcome was known).
‡The MAGNET neuroprotective study is shown here but did not contribute to the analyses (no events in the control group).
†p-value for heterogeneity = 0.49 (the heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and
trial in a generalising estimating equation [GEE] model).
https://doi.org/10.1371/journal.pmed.1002398.t007
Table 8. Maternal secondary outcomes*.
Outcome Studies contributing data MgSO4 Control RR LCL UCL p†
Dichotomous
Adverse event leading to stopping treatment 9,10,11,12,13 115/2,310 (5.0%) 58/2,337 (2.5%) 1.95 1.44 2.65 0.11
Intrapartum fever treated with antibiotics 9,11 237/603 (39.3%) 227/592 (38.3%) 1.05 0.94 1.18 0.37
Clinical chorioamnionitis during labour 9,11,13 323/1,695 (19.1%) 326/1,738 (18.8%) 1.00 0.87 1.14 0.92
Caesarean delivery 9,10,11,12,13 1,310/2,727 (48.0%) 1,282/2,766 (46.3%) 1.04 0.98 1.10 0.38
Postpartum haemorrhage 9,10,11,12 410/1,457 (28.1%) 410/1,458 (28.1%) 1.01 0.90 1.13 0.99
Abbreviations: LCL, lower confidence limit; UCL, upper confidence limit. The trials included are as follows: 9 = Australasian Collaborative Trial of
Magnesium Sulphate (ACTOMgSO4), 10 = PREterm brain protection by MAGnesium sulphate (PREMAG), 11 = Magnesium and Neurologic Endpoints
Trial (MAGNET), 12 = MAGnesium sulphate for Prevention of Eclampsia (MAGPIE), and 13 = Beneficial Effects of Antenatal Magnesium Sulfate (BEAM).
*Overall results from 1-stage individual participant data (IPD).
†p-values for heterogeneity (the heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and trial in a
generalising estimating equation [GEE] model).
https://doi.org/10.1371/journal.pmed.1002398.t008
Magnesium sulphate for fetal neuroprotection
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002398 October 4, 2017 12 / 24
or 4), cystic periventricular leucomalacia (PVL), neonatal convulsions, neonatal encephalopa-
thy, chronic lung disease/bronchopulmonary dysplasia (BPD), posthaemorrhagic hydrocepha-
lus or ventriculomegaly, proven systemic infection, necrotising enterocolitis (NEC), patent
ductus arteriosus (PDA) requiring treatment, any retinopathy of prematurity (ROP), or severe
neonatal adverse outcome (death, BPD, PDA, NEC, stage 3 or worse ROP, or grade 3 or 4
IVH); or the continuous outcomes (weight, head circumference, or length at birth) (Table 9).
There was, however, a slightly lower birthweight z-score (mean difference −0.05, 95% CI −0.10
to −0.00; p = 0.04), a result obtained with no significant heterogeneity among the trials
(p = 0.82) (Table 9).
Table 9. Neonatal secondary outcomes*.
Outcome Studies contributing
data
MgSO4 Control RR LCL UCL p†
Dichotomous
Apgar score < 7 at 5 minutes 9,10,11,12,13 414/2,903 (14.3%) 420/2,961 (14.2%) 1.01 0.89 1.14 0.38
Active resuscitation at birth 9,10,12,13 1,218/2,836 (42.9%) 1,284/2,891 (44.4%) 0.99 0.96 1.02 0.46
Respiratory distress syndrome 9,10,11,13 1,288/2,215 (58.1%) 1,325/2,268 (58.4%) 1.01 0.97 1.05 0.46
Ongoing use of respiratory support 9,10,11,12,13 1,544/2,667 (57.9%) 1,612/2,710 (59.5%) 1.00 0.97 1.03 0.10
Chronic lung disease/BPD 9,10,11,13 442/2,223 (19.9%) 420/2,273 (18.5%) 1.08 0.96 1.22 0.56
Neonatal convulsions 9,10,11,12,13 68/2,884 (2.4%) 89/2,930 (3.0%) 0.75 0.54 1.03 0.91
Any IVH 9,10,11,13 461/2,149 (21.5%) 482/2,202 (21.9%) 0.98 0.87 1.09 0.37
Grade 3 or 4 IVH 9,10,11,13 96/2,149 (4.5%) 114/2,202 (5.2%) 0.83 0.63 1.09 0.48
Cystic PVL 9,10,11,13 70/2,044 (3.4%) 76/2,089 (3.6%) 0.91 0.66 1.25 0.90
Posthaemorrhagic hydrocephaly or
ventriculomegaly
9,10,11 57/1,000 (5.7%) 53/976 (5.4%) 1.06 0.73 1.53 0.78
Proven neonatal systemic infection 9,10,11,13 432/2,213 (19.5%) 417/2,266 (18.4%) 1.06 0.94 1.20 0.47
Necrotising enterocolitis 9,10,11,13 155/2,142 (7.2%) 131/2,190 (6.0%) 1.22 0.97 1.53 0.56
Patent ductus arteriosus requiring
treatment
9,10,11,13 425/2,214 (19.2%) 432/2,264 (19.1%) 1.03 0.91 1.16 0.50
Any retinopathy of prematurity 9,10,11,13 470/1,977 (23.8%) 469/2,023 (23.2%) 1.03 0.92 1.15 0.75
Severe neonatal adverse outcome# 9,10,11,13 1,021/2,225 (45.9%) 1,011/2,282 (44.3%) 1.03 0.97 1.10 0.44
Continuous Mean (SE) Mean (SE) Mean
difference
LCL UCL p†




0.0 −0.1 0.2 0.95




−0.05 −0.10 −0.00 0.82
Birth weight (g)§ 9,10,11,12,13 1,459 (12) (n = 2,987) 1,471 (12) (n = 3,057) −10 −41 21 0.96
Birth head circumference (cm)§ 9,10,11,13 26.8 (0.1) (n = 2,038) 26.8 (0.1) (n = 2,091) 0.0 −0.2 0.2 0.87
Birth length (cm)§ 9,10,11,13 38.4 (0.1) (n = 1,954) 38.5 (0.1) (n = 2,009) −0.0 −0.3 0.3 0.85
Abbreviations: BPD, bronchopulmonary dysplasia; IVH, intraventricular haemorrhage; LCL, lower confidence limit; PVL, periventricular leucomalacia; RR,
relative risk; SE, standard error; UCL, upper confidence limit. The trials included are as follows: 9 = Australasian Collaborative Trial of Magnesium Sulphate
(ACTOMgSO4), 10 = PREterm brain protection by MAGnesium sulphate (PREMAG), 11 = Magnesium and Neurologic Endpoints Trial (MAGNET),
12 = MAGnesium sulphate for Prevention of Eclampsia (MAGPIE), and 13 = Beneficial Effects of Antenatal Magnesium Sulfate (BEAM).
*Overall results from 1-stage individual participant data (IPD).
#Any of the following: death, chronic lung disease, patent ductus arteriosus requiring treatment, neonatal encephalopathy, necrotising enterocolitis, stage 3
or worse retinopathy of prematurity, or grade 3 or 4 intraventricular haemorrhage (IVH).
†Heterogeneity p-values for 1-stage analyses.
§Adjusted for age and sex.
https://doi.org/10.1371/journal.pmed.1002398.t009
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Paediatric secondary outcomes
The meta-analysis found no evidence of statistically significant differences or significant het-
erogeneity for any of the analyses for the follow-up outcomes reported or defined by the trial-
ists. Of note, weight z-scores at follow-up did not clearly differ between groups (Table 10).
Subgroup analyses
As there were no events, the planned subgroup analyses for severe maternal adverse outcomes
potentially related to treatment were not possible. Not all trials had data available to contribute
to all subgroup analyses.
A. Primary reason pregnancy was considered to be at raised risk of preterm birth.
Among the 4 trials able to contribute data to this analysis, there were no clear differences in
treatment effects among the subgroups considered by individual causes for the high-risk preg-
nancy (Table 11).
B. Purpose of treatment: Neuroprotection of the fetus versus other purpose. There was
a significant difference in the magnitude of the treatment effect for death or CP for studies
with the intent of fetal neuroprotection compared with studies with a different purpose. A
Table 10. Paediatric secondary outcomes*.
Outcome Studies contributing
data
MgSO4 Control RR LCL UCL p†
Dichotomous follow-up outcomes
Blind 9,10,12,13 92/1,332 (6.9%) 128/1,383 (9.3%) 0.83 0.65 1.06 0.99
Deaf 9,10,11,12,13 83/1,094 (7.6%) 83/1,167 (7.1%) 1.10 0.83 1.47 0.99
Developmental delay: any 9,10,12,13 674/1,985 (34.0%) 706/2,027 (34.8%) 0.99 0.91 1.08 0.86
Gross motor dysfunction: any 9,10,13 239/1,707 (14.0%) 279/1,715 (16.3%) 0.85 0.72 1.00 0.47
Gross motor dysfunction: moderate or
severe
9,10,13 55/1,707 (3.2%) 70/1,715 (4.1%) 0.78 0.55 1.11 0.69
Neurosensory disability: any 9,10,11,12,13 795/2,283 (34.8%) 851/2,339 (36.4%) 0.98 0.90 1.05 0.65
Major neurosensory disability 9,10,12,13 404/2,222 (18.2%) 427/2,277 (18.8%) 1.00 0.88 1.13 0.43




0.99 0.93 1.05 0.09
Death or major neurosensory disability 9,10,11,12,13 839/3,046 (27.5%) 848/3,085 (27.5%) 1.01 0.93 1.10 0.13
Death or moderate/severe motor
dysfunction
9,10,13 281/2,170 (12.9%) 312/2,220 (14.1%) 0.91 0.78 1.06 0.40
Continuous follow-up outcomes Mean (SE) Mean (SE) Mean
difference
LCL UCL p†




0.04 −0.09 0.16 0.55




−0.06 −0.21 0.09 0.34
Head circumference§ 9,10 48.6 (0.07) (n = 779) 48.5 (0.07) (n = 732) 0.1 −0.1 0.3 0.24
Abbreviations: LCL, lower confidence limit; RR, relative risk; SE, standard error; UCL, upper confidence limit. The trials included are as follows:
9 = Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4), 10 = PREterm brain protection by MAGnesium sulphate (PREMAG),
11 = Magnesium and Neurologic Endpoints Trial (MAGNET), 12 = MAGnesium sulphate for Prevention of Eclampsia (MAGPIE), and 13 = Beneficial Effects
of Antenatal Magnesium Sulfate (BEAM).
*Overall results from 1-stage individual participant data (IPD).
†Heterogeneity p-values for 1-stage analyses.
§Adjusted for age and sex.
https://doi.org/10.1371/journal.pmed.1002398.t010
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significant reduction in death or CP was seen in the ‘neuroprotection’ group, but not in the
‘other’ reason group. There were no clear differences in treatment effects for the other out-
comes (Table 12).
C. Multiple birth. There were no clear differences in treatment effects among the sub-
groups considered by multiple birth (Table 13).
D. Gestational age at randomisation. Inclusion criteria for gestational age at trial entry
varied across trials. Several different, prespecified combinations of gestational age groupings
were considered. No obvious monotonic trends were seen for any of the major outcomes
when categorised by gestational age when first treated, and no statistically significant heteroge-
neity was observed among any subgroups (Table 14, S2 Table).
E. Time from first treatment until birth. Several different, prespecified combinations of
time from first treatment to birth were considered. No obvious linear trends were seen for any
Table 11. Treatment effects by the individual reasons why the pregnancy was considered to be high risk.
Outcome Subgroup Included trials MgSO4 Control RR LCL UCL p†
Death or CP Preeclampsia 9,12 215/883 (24.3%) 195/866 (22.5%) 1.06 0.89 1.26 0.15
Preterm labour 9,10,11 91/477 (19.1%) 109/484 (22.5%) 0.82 0.63 1.06 –
Chorioamnionitis 9,10 32/133 (24.1%) 32/141 (22.7%) 1.06 0.68 1.66 –
APH 10 8/47 (17.0%) 13/40 (32.5%) 0.53 0.23 1.24 –
PROM < 24 hours 9,10 3/31 (9.7%) 6/34 (17.6%) 0.64 0.17 2.42 –
PROM 24 hours 10,11 25/144 (17.4%) 12/122 (9.8%) 1.69 0.87 3.25 –
Other 9,10 11/63 (17.5%) 18/55 (32.7%) 0.53 0.28 1.02 –
Death (at any time) Preeclampsia 9,12 207/883 (23.4%) 187/866 (21.6%) 1.07 0.89 1.27 0.34
Preterm labour 9,10 58/438 (13.2%) 72/443 (16.3%) 0.77 0.55 1.08 –
Chorioamnionitis 9,10 26/133 (19.5%) 25/141 (17.7%) 1.17 0.70 1.95 –
APH 10 6/47 (12.8%) 7/40 (17.5%) 0.85 0.28 2.62 –
PROM < 24 hours 9,10 1/31 (3.2%) 4/34 (11.8%) 0.30 0.03 2.68 –
PROM 24 hours 10,11 11/144 (7.6%) 5/122 (4.1%) 1.71 0.59 4.90 –
Other 9,10 8/63 (12.7%) 14/55 (25.5%) 0.53 0.24 1.17 –
Cerebral palsy* Preeclampsia 9,12 8/320 (2.50%) 8/325 (2.5%) 0.95 0.37 2.44 0.48
Preterm labour 9,10,11 27/401 (6.7%) 37/395 (9.4%) 0.71 0.45 1.14 –
Chorioamnionitis 9,10 6/107 (5.6%) 7/116 (6.0%) 0.87 0.31 2.49 –
APH 10 2/41 (4.9%) 6/32 (18.8%) 0.26 0.06 1.19 –
PROM 24 hours 10 11/96 (11.5%) 7/80 (8.8%) 1.27 0.51 3.20 –
Death or major neurosensory disability Preeclampsia 9,12 227/883 (25.7%) 207/866 (23.9%) 1.06 0.90 1.25 0.53
Preterm labour 9,10 112/438 (25.6%) 126/443 (28.4%) 0.88 0.70 1.11 –
Chorioamnionitis 9,10 35/133 (26.3%) 32/141 (22.7%) 1.24 0.80 1.91 –
APH 9,10 9/47 (19.1%) 9/43 (20.9%) 1.14 0.44 2.92 –
PROM < 24 hours 9,10 4/31 (12.9%) 11/34 (32.4%) 0.50 0.18 1.38 –
PROM 24 hours 9 12/105 (11.4%) 9/86 (10.5%) 1.05 0.45 2.41 –
Other 9,10 16/63 (25.4%) 21/55 (38.2%) 0.70 0.41 1.19 –
Abbreviations: APH, antepartum haemorrhage; CP, cerebral palsy; LCL, lower confidence limit; PROM, prelabour rupture of membranes; RR, relative risk;
UCL, 95% upper confidence limit. The trials included are as follows: 9 = Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4),
10 = PREterm brain protection by MAGnesium sulphate (PREMAG), 11 = Magnesium and Neurologic Endpoints Trial (MAGNET), 12 = MAGnesium
sulphate for Prevention of Eclampsia (MAGPIE) and 13 = Beneficial Effects of Antenatal Magnesium Sulfate (BEAM).
*Some subgroups were not included as no events were observed.
†p-values for heterogeneity (the heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and
subgroup in a generalising estimating equation [GEE] model).
https://doi.org/10.1371/journal.pmed.1002398.t011
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of the major outcomes when categorised by time from when first treated until birth, and no
significant heterogeneity was observed among any subgroups (Table 15 and S3 Table).
F. Total dose received. The total dose of MgSO4 received varied by trial because of differ-
ent treatment protocols; therefore, the effect of increased dose on primary outcomes was
explored. Several different, prespecified combinations of dosage groupings were considered.
No obvious linear trends were seen for any of the major outcomes when categorised by dose
received, and no significant heterogeneity was observed (Table 16 and S4 Table).
G. Maintenance therapy received. There were no clear differences in treatment effects
among the subgroups considered by whether maintenance therapy had been received or not
(Table 17).
H. Whether repeat antenatal magnesium sulphate treatment was received. No trial was
able to provide data to contribute to this planned subgroup analysis.
Table 12. Treatment effects among the subgroups considered by the purpose of the treatment.
Outcome Subgroup Included trials MgSO4 Control RR LCL UCL p†
Death or CP Neuroprotection fetus 9,10,11,13 332/2,198 (15.1%) 392/2,250 (17.4%) 0.86 0.75 0.99 0.04
Other 11,12 210/848 (24.8%) 185/835 (22.2%) 1.08 0.91 1.29
Death (at any time) Neuroprotection fetus 9,10,11,13 228/2,198 (10.4%) 244/2,250 (10.8%) 0.95 0.80 1.13 0.19
Other 11,12 208/848 (24.5%) 177/835 (21.2%) 1.12 0.93 1.33
Cerebral palsy Neuroprotection fetus 9,10,11,13 104/2,002 (5.2%) 149/2,032 (7.3%) 0.70 0.55 0.90 0.22
Other 11,12 2/273 (0.7%) 8/294 (2.7%) 0.27 0.06 1.24
Death or major neurosensory disability Neuroprotection fetus 9,10,11,13 622/2,198 (28.3%) 659/2,250 (29.3%) 0.99 0.90 1.09 0.29
Other 11,12 217/848 (25.6%) 189/835 (22.6%) 1.10 0.92 1.30
Abbreviations: CP, cerebral palsy; LCL, lower confidence limit; RR, relative risk; UCL, upper confidence limit. The trials included are as follows:
9 = Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4), 10 = PREterm brain protection by MAGnesium sulphate (PREMAG),
11 = Magnesium and Neurologic Endpoints Trial (MAGNET), 12 = MAGnesium sulphate for Prevention of Eclampsia (MAGPIE), and 13 = Beneficial Effects
of Antenatal Magnesium Sulfate (BEAM).
†p-values for heterogeneity (the heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and
subgroup in a generalising estimating equation [GEE] model).
https://doi.org/10.1371/journal.pmed.1002398.t012
Table 13. Treatment effects among the subgroups considered by multiple birth.
Outcome Subgroup Included trials MgSO4 n/N (%) Control n/N (%) RR LCL UCL p†
Death or CP Singleton 9,10,11,12,13 429/2,446 (17.5%) 462/2,472 (18.7%) 0.94 0.83 1.05 0.55
Multiple 9,10,11,13 90/517 (17.4%) 109/541 (20.1%) 0.86 0.65 1.16 –
Death (at any time) Singleton 9,10,11,12,13 347/2,446 (14.2%) 345/2,472 (14.0%) 1.01 0.88 1.16 0.88
Multiple 9,10,11,13 66/517 (12.8%) 70/541 (12.9%) 0.99 0.68 1.43 –
Cerebral palsy Singleton 9,10,11,12,13 82/1,783 (4.6%) 117/1,804 (6.5%) 0.70 0.53 0.92 0.68
Multiple 9,10,13 24/453 (5.3%) 40/474 (8.4%) 0.64 0.38 1.07 –
Death or major neurosensory disability Singleton 9,10,11,12,13 674/2,446 (27.6%) 672/2,472 (27.2%) 1.02 0.93 1.11 0.30
Multiple 9,10,13 136/496 (27.4%) 169/526 (32.1%) 0.91 0.73 1.14 –
Abbreviations: CP, cerebral palsy; LCL, lower confidence limit; RR, relative risk; UCL, upper confidence limit. The trials included are as follows:
9 = Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4), 10 = PREterm brain protection by MAGnesium sulphate (PREMAG),
11 = Magnesium and Neurologic Endpoints Trial (MAGNET), 12 = MAGnesium sulphate for Prevention of Eclampsia (MAGPIE), and 13 = Beneficial Effects
of Antenatal Magnesium Sulfate (BEAM).
†p-values for heterogeneity (the heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and
subgroup in a generalising estimating equation [GEE] model).
https://doi.org/10.1371/journal.pmed.1002398.t013
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Sensitivity analyses to account for missing data
Regardless of the methods used to account for missing data, no conclusions were altered com-
pared with the main results reported above for any of the outcomes (S5 Table).
Discussion
Summary of evidence
The major finding from this IPD-MA is that for women at risk of imminent preterm birth
antenatal, magnesium sulphate reduces the risk of their baby developing CP, with a NNT to
benefit of 46 babies. The neuroprotective effect is confirmed when the primary reason for giv-
ing the antenatal magnesium sulphate is for neuroprotection of the fetus. Importantly, this
benefit is not at the expense of an increase in mortality for the baby, and there appear to be no
substantial short- or long-term complications for the mother or fetus from treatment with
antenatal magnesium sulphate.
The results from this IPD-MA are consistent with the findings of the existing aggregate
data meta-analysis in the Cochrane Library [14]. The new information that this IPD-MA has
been able to clarify is that no particular subgroup of women and babies benefitted more or less
from treatment among varying reasons for preterm birth, varying preterm gestational ages
when treatment was started, or with varying dosage regimens, including whether maintenance
Table 14. Treatment effects among the subgroups of gestational age when treatment first given.
Outcome GA (weeks) Included trials MgSO4 Control RR LCL UCL p†
Death or CP <26 9,10,11,12,13 206/527 (39.1%) 223/531 (42.0%) 0.99 0.87 1.12 0.78‡
26–27 9,10,11,12,13 107/512 (20.9%) 132/569 (23.2%) 0.91 0.75 1.12 –
28–29 9,10,11,12,13 98/732 (13.4%) 98/706 (13.9%) 1.00 0.80 1.26 –
30–31 10,11,12,13 60/629 (9.54%) 58/643 (9.02%) 1.04 0.75 1.44 –
32+ 10,11,12 71/641 (11.1%) 66/632 (10.4%) 1.06 0.78 1.46 –
Death (at any time) <26 9,10,11,12,13 169/527 (32.1%) 169/531 (31.8%) 1.06 0.92 1.22 0.86‡
26–27 9,10,11,12,13 77/512 (15.0%) 89/569 (15.6%) 1.00 0.78 1.26 –
28–29 9,10,11,12,13 71/732 (9.7%) 60/706 (8.5%) 1.14 0.87 1.49 –
30–31 10,11,12,13 50/629 (8.0%) 42/643 (6.5%) 1.18 0.82 1.70 –
32+ 10,11,12 69/641 (10.8%) 61/632 (9.7%) 1.12 0.81 1.54 –
Cerebral palsy <28 9,10,11,13 67/837 (8.0%) 98/876 (11.2%) 0.69 0.52 0.93 0.85
28–31 9,10,11,12,13 37/1150 (3.2%) 54/1154 (4.7%) 0.69 0.45 1.05 –
32+ 10,12 2/253 (0.8%) 5/264 (1.9%) 0.42 0.08 2.14 –
Death or major neurosensory disability <26 9,10,11,12,13 305/527 (57.9%) 298/531 (56.1%) 1.05 0.95 1.16 0.72
26–27 9,10,11,12,13 154/512 (30.1%) 194/569 (34.1%) 0.93 0.79 1.10 –
28–29 9,10,11,12,13 179/732 (24.5%) 161/706 (22.8%) 1.07 0.90 1.28 –
30–31 10,11,12,13 125/629 (19.9%) 127/643 (19.8%) 1.04 0.83 1.30 –
32+ 10,11,12,13 76/645 (11.8%) 68/634 (10.7%) 1.10 0.81 1.49 –
Abbreviations: CP, cerebral palsy; GA, gestational age; LCL, lower confidence limit; RR, relative risk; UCL, upper confidence limit. The trials included are as
follows: 9 = Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4), 10 = PREterm brain protection by MAGnesium sulphate (PREMAG),
11 = Magnesium and Neurologic Endpoints Trial (MAGNET), 12 = MAGnesium sulphate for Prevention of Eclampsia (MAGPIE), and 13 = Beneficial Effects
of Antenatal Magnesium Sulfate (BEAM).
†p-values for heterogeneity (the heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and
subgroup in a generalising estimating equation [GEE] model).
‡Heterogeneity p-value derived from logistic model due to nonconvergence of model containing treatment x subgroup interaction term.
https://doi.org/10.1371/journal.pmed.1002398.t014
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therapy was given after a loading dose or not. Consequently, the information from the
IPD-MA shows that there are no particular subgroups of women or their babies who might
benefit more from treatment compared to others. The IPD-MA shows that antenatal magne-
sium sulphate reduces not only all CP, the majority of which is mild, but also moderate and
severe combined and severe CP alone. Of note, the beneficial effect of magnesium sulphate on
CP was not associated with fewer severe cerebral morbidities such as grade 3–4 intraventricu-
lar haemorrhage or cystic periventricular leucomalacia.
No severe adverse maternal events (including death or respiratory or cardiac arrest) were
recorded for the 2 studies able to provide data for this IPD-MA. While reassuring, information
about these rare maternal events should be routinely collected [26]. In combination with the
known but less serious side effects of magnesium sulphate, such as flushing and tachycardia,
the fact that maternal side effects are more likely to lead to stopping of a beneficial treatment
than placebo and that severe maternal events are possible highlight the importance of giving
magnesium sulphate under appropriate supervision [26,27].
The lack of an effect of magnesium sulphate on Apgar scores at 5 minutes, a need for active
resuscitation at birth, or a need for ongoing assisted ventilation after birth indicates that mag-
nesium sulphate, as used in these trials, does not have any substantial effect on depressing
infant breathing after birth, either immediately or in the early hours and days of life, after
which time the drug would usually have been excreted through the urinary system.
Table 15. Treatment effects by subgroups according to the time from the start of treatment until birth.
Outcome Time (hours) Included trials MgSO4 Control RR LCL UCL p†
Death or CP 0 to <4 9,10,11,12 141/808 (17.5%) 157/822 (19.1%) 0.91 0.74 1.13 0.11
4 to <8 9,10,12 35/195 (17.9%) 27/191 (14.1%) 1.24 0.77 1.99 –
8 to <12 9,10,12 15/95 (15.8%) 29/84 (34.5%) 0.49 0.27 0.87 –
12 to <24 9,10,12 49/193 (25.4%) 45/182 (24.7%) 1.00 0.70 1.42 –
24 to <36 9,12 25/70 (35.7%) 15/57 (26.3%) 1.34 0.78 2.29 –
36+ 9,11,12 117/446 (26.2%) 116/394 (29.4%) 0.92 0.73 1.14 –
Death (at any time) 0 to <4 9,10,11,12 101/808 (12.5%) 104/822 (12.7%) 1.01 0.77 1.32 0.23
4 to <8 9,10,12 26/195 (13.3%) 20/191 (10.5%) 1.30 0.73 2.31 –
8 to <12 9,10,12 15/95 (15.8%) 26/84 (31.0%) 0.55 0.31 1.00 –
12 to <24 9,11,12 43/193 (22.3%) 41/182 (22.5%) 0.96 0.66 1.40 –
24 to <36 9,12 24/70 (34.3%) 14/57 (24.6%) 1.38 0.79 2.41 –
36+ 9,11,12 112/446 (25.1%) 110/394 (27.9%) 0.93 0.74 1.17 –
Cerebral palsy 0 to <4 9,10,11 40/558 (7.2%) 53/551 (9.6%) 0.75 0.50 1.12 0.77
4 to <12 9,10,12 9/186 (4.8%) 10/162 (6.2%) 0.71 0.30 1.68 –
12+ 9,10,11,12 13/320 (4.1%) 11/282 (3.9%) 1.13 0.47 2.68 –
Death or major neurosensory disability 0 to <4 9,10,11,12 164/808 (20.3%) 173/822 (21.0%) 1.00 0.82 1.21 0.24
4 to <8 9,10,12 44/195 (22.6%) 30/191 (15.7%) 1.32 0.86 2.03 –
8 to <12 9,10,12 20/95 (21.1%) 30/84 (35.7%) 0.64 0.39 1.05 –
12 to <24 9,11,12 52/193 (26.9%) 48/182 (26.4%) 0.99 0.70 1.39 –
24 to <36 9,12 29/70 (41.4%) 18/57 (31.6%) 1.27 0.79 2.03 –
36+ 9,11,12 126/446 (28.3%) 125/394 (31.7%) 0.94 0.76 1.16 –
Abbreviations: CP, cerebral palsy; LCL, lower confidence limit; RR, relative risk; UCL, upper confidence limit. The trials included are as follows:
9 = Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4), 10 = PREterm brain protection by MAGnesium sulphate (PREMAG),
11 = Magnesium and Neurologic Endpoints Trial (MAGNET), and 12 = MAGnesium sulphate for Prevention of Eclampsia (MAGPIE).
†p-values for heterogeneity (The heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and
subgroup in a generalising estimating equation [GEE] model).
https://doi.org/10.1371/journal.pmed.1002398.t015
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There were no substantial relationships between time from starting magnesium treatment
until birth, the total dose received, or whether maintenance treatment was received and any of
the major health outcomes. As these events all occur postrandomisation and therefore may be
affected by the treatment given, interpretation of the results must be cautious. With maternal
side effects increasing with higher total dose [26] and with concerns about maternal safety, at a
clinical level it may be prudent to limit treatment to times close to birth and to minimise the
dose of magnesium used to a 4-g bolus loading dose with or without a maintenance dose of
1 g/hour.
Strengths and limitations
IPD-MA is recognised as the gold standard for systematic reviews [17]. One of the strengths of
this study is that we have been able to include individual participant data from all of the
known completed randomised clinical trials of magnesium sulphate for which developmental
outcomes for the child have been reported.
Table 16. Treatment effects among the subgroups considered by dose actually received.
Outcome Dose (g) Included trials MgSO4 Control RR LCL UCL p†
Death or CP 0 to <4 9,10,11,13 18/133 (13.5%) 20/141 (14.2%) 0.96 0.52 1.75 0.80
4 to <14 9,10,11,13 178/963 (18.5%) 205/955 (21.5%) 0.86 0.72 1.04 –
14 to <28 9,13 26/166 (15.7%) 42/191 (22.0%) 0.70 0.45 1.11 –
28 to <42 13 75/598 (12.5%) 92/623 (14.8%) 0.86 0.64 1.15 –
42 to <56 13 16/174 (9.20%) 18/186 (9.68%) 0.95 0.49 1.82 –
56+ 11,13 24/191 (12.6%) 15/152 (9.87%) 1.23 0.65 2.32 –
Death (at any time) 0 to <4 9,10,11,13 10/133 (7.52%) 15/141 (10.6%) 0.73 0.35 1.51 0.81
4 to <14 9,10,11,13 126/963 (13.1%) 131/955 (13.7%) 0.97 0.76 1.23 –
14 to <28 9,13 18/166 (10.8%) 24/191 (12.6%) 0.81 0.44 1.50 –
28 to <42 13 51/598 (8.53%) 52/623 (8.35%) 1.02 0.70 1.48 –
42 to <56 13 12/174 (6.90%) 14/186 (7.53%) 0.91 0.43 1.90 –
56+ 13 13/168 (7.74%) 7/148 (4.73%) 1.63 0.65 4.05 –
Cerebral palsy 0 to <4 9,10,11,13 8/119 (6.72%) 5/124 (4.03%) 1.71 0.50 5.80 0.44
4 9,10,11 21/328 (6.40%) 32/283 (11.3%) 0.57 0.33 0.98 –
4 to <14 9,13 31/503 (6.16%) 40/530 (7.55%) 0.82 0.52 1.28 –
14 to <28 9,13 8/149 (5.37%) 18/176 (10.2%) 0.50 0.23 1.13 –
28+ 13 36/900 (4.00%) 52/911 (5.71%) 0.70 0.46 1.07 –
Death or major neurosensory disability 0 to <4 9,10,11,13 26/133 (19.5%) 28/141 (19.9%) 1.01 0.63 1.64 0.11
4 to <14 9,10,11,13 244/963 (25.3%) 259/955 (27.1%) 0.98 0.83 1.14 –
14 to <28 9,13 47/166 (28.3%) 76/191 (39.8%) 0.72 0.53 0.98 –
28 to <42 13 204/598 (34.1%) 215/623 (34.5%) 1.00 0.85 1.18 –
42 to <56 13 50/174 (28.7%) 44/186 (23.7%) 1.25 0.87 1.79 –
56+ 13 52/168 (31.0%) 33/148 (22.3%) 1.40 0.95 2.07 –
Abbreviations: CP, cerebral palsy; LCL, lower confidence limit; RR, relative risk; UCL, upper confidence limit. The trials included are as follows:
9 = Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4), 10 = PREterm brain protection by MAGnesium sulphate (PREMAG),
11 = Magnesium and Neurologic Endpoints Trial (MAGNET), 12 = MAGnesium sulphate for Prevention of Eclampsia (MAGPIE), and 13 = Beneficial Effects
of Antenatal Magnesium Sulfate (BEAM). No significant interaction terms were observed for any endpoint when total dose was analysed as a continuous
variable. Total dose itself was not significant in the model either.
†p-values for heterogeneity (the heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and
subgroup in a generalising estimating equation [GEE] model).
https://doi.org/10.1371/journal.pmed.1002398.t016
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We are aware of 2 ongoing placebo-controlled trials of antenatal magnesium sulphate for
neuroprotection of the fetus that will report on childhood development: one in women at risk
of preterm birth from 24 to<32 weeks’ gestation with a sample size of 500 [24] that is due to
report in 2018 and the other where preterm birth is expected or planned between 30 to<34
weeks’ gestation, with a planned sample size of 1,676 babies and expected to report in 2021
[25]. Ultimately, data from these trials will be eligible to contribute to an update of this
IPD-MA.
The limitations of our study are that not all trials had collected or could provide the data
required for all of the prespecified analyses. Given that maternal and fetal event rates are low
for some important clinical events, the power to find any overall or subgroup differences was
limited. Lack of data from individual studies compounded the problem of low power for some
of the analyses. Several of the planned analyses were for events that occurred after randomisa-
tion, including total dose received and the duration between start of treatment and birth. We
recognise that such events are more subject to bias, but our intent was to identify subgroups of
mothers who benefitted most and thus enable use of antenatal magnesium sulphate therapy to
be better targeted.
Conclusions
This IPD meta-analysis reaffirms that antenatal magnesium sulphate given prior to preterm
birth is neuroprotective for CP and reduces the combined risk of fetal/infant death or CP,
when the primary intent of magnesium sulphate treatment is fetal neuroprotection. Antenatal
magnesium sulphate is a relatively inexpensive, easy to administer, effective treatment that can
reduce the burden of death and CP facing babies born very preterm. Widespread adoption of
the recommendations to use magnesium sulphate within several national clinical practice
guidelines [15,16,28,29] and now within the recent WHO recommendations on interventions
to improve preterm birth outcomes [3] could lead to significant global health benefits.
It is reassuring that antenatal magnesium sulphate does not appear to substantially depress
the breathing efforts of babies either at birth or in the first hours of life. It is also reassuring
that benefit is seen regardless of the reason for preterm birth and that antenatal magnesium
Table 17. Treatment effects among the subgroups considered by whether maintenance therapy was received or not.
Outcome Maintenance Included trials MgSO4 Control RR LCL UCL p†
Death or CP No‡ 9,10 73/458 (15.9%) 90/417 (21.6%) 0.73 0.54 0.98 0.34
Yes§ 9,11 113/579 (19.5%) 129/559 (23.1%) 0.87 0.69 1.11
Death (at any time) No‡ 9,10 48/458 (10.5%) 52/417 (12.5%) 0.83 0.56 1.23 0.99
Yes§ 9,11 80/579 (13.8%) 94/559 (16.8%) 0.83 0.62 1.11
Cerebral palsy No‡ 9,10 25/401 (6.23%) 38/356 (10.7%) 0.59 0.36 0.97 0.17
Yes§ 9,11 33/481 (6.86%) 35/460 (7.61%) 0.94 0.59 1.49
Death or major neurosensory disability No‡ 9,10 72/458 (15.7%) 81/417 (19.4%) 0.81 0.60 1.09 0.26
Yes§ 9,11 162/579 (28.0%) 166/559 (29.7%) 1.00 0.82 1.21
Abbreviations: CP, cerebral palsy; LCL, lower confidence limit; RR, relative risk; UCL, upper confidence limit. The trials included are as follows:
9 = Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4), 10 = PREterm brain protection by MAGnesium sulphate (PREMAG), and
11 = Magnesium and Neurologic Endpoints Trial (MAGNET).
†p-values for heterogeneity for 1-stage analyses are from Wald chi-square tests for the interaction between treatment and subgroup in a generalising
estimating equation (GEE) model.
‡At least some of the loading dose was received.
§The full loading dose was received, plus at least some of the maintenance dose
https://doi.org/10.1371/journal.pmed.1002398.t017
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sulphate has similar effects across a range of preterm gestational ages. As there is minimal vari-
ation in outcomes related to time to birth and with dosage, it would be prudent to restrict
administration of antenatal magnesium sulphate for fetal neuroprotection to close to the
expected or planned birth and to use 4 g, the smallest effective dose, with or without a 1 g/hour
maintenance dose.
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